CanSino Bio Photo:VCG
The AD5-nCOV vaccine candidate developed by Chinese biopharmaceutical company CanSino Biologics has met its pre-specified primary safety and efficacy criteria at interim analysis, with no serious adverse events, and the company will continue to advance its phase III clinical trial of the vaccine.
The phase III clinical trial of Ad5-nCoV saw more than 40,000 volunteers administered with the vaccine in 78 clinical trial sites across five countries in three continents, according to a notice CanSino Biologics sent to the Global Times on Monday.
The company is expected to obtain the interim data of its phase-three clinical trials across the world this week after they are unblinded, the Global Times learned.
CanSino said it has completed case accrual for the interim analysis of the phase III clinical trial of Ad5-nCoV, and the data from these cases has been submitted to the Independent Data Monitoring Committee (IDMC) for analysis and recommendation.
The Ad5-nCoV vaccines is a recombinant adenovirus vector vaccine jointly developed by CanSino Biologics and researchers from the Institute of Military Medicine under the Academy of Military Sciences led by Chen Wei.
The COVID-19 vaccines developed by AstraZeneca and Johnson & Johnson use a similar approach.